Arthritis sufferers and those with a financial interest in their pain will be watching closely this week as two U.S. Food and Drug Administration committees debate the future for a group of pain medicines recently hobbled by safety concerns.
That discussion, set to begin today at the FDA, follows the Bush administration's announcement yesterday that it is creating a new drug safety board that will help federal officials uncover problems with medicines after they hit the market.
Both efforts are in response to the September decision by the drug maker Merck & Co. to pull the blockbuster arthritis medicine Vioxx from the market. The New Jersey company did so after research suggested an increased risk of heart attacks and stroke among patients taking the medicine, which was used by about 2 million people worldwide.
Since then, FDA has issued safety bulletins about Celebrex and Bextra, two other still-available medicines in the same class of anti-arthritis drugs called cox-2 inhibitors. The class is named for the enzyme involved in the pain and inflammation that the drugs inhibit. The drugs have been popular because they offer pain relief without the stomach problems caused by older arthritis medicines.
IMS Health, a market research firm, reported this week that prescriptions filled for cox-2 inhibitors were down 43 percent in December from the previous year.
The decrease might have been even more dramatic in Pennsylvania, where prescriptions for the group of drugs in the state's PACE program for low-income seniors dropped by nearly 60 percent between September and last month.
"We're watching very anxiously ... to see what the outcome of the hearings will be," said Tom Snedden, director of the state's PACE, or Pharmaceutical Assistance Contract for the Elderly, program. "We want to see if there's any evidence that Celebrex and Bextra have the same issues as Vioxx, and, if they do, then we're prepared to discontinue reimbursing for them."
In the midst of the cox-2 controversies, critics have called for several FDA reforms, including an improved system for tracking safety problems after medicines have been approved for use.
The new Drug Safety Oversight Board, announced yesterday by Health and Human Services Secretary Mike Leavitt, will do some of that. Emerging data and risk information will be posted on a new "Drug Watch" Web page, Leavitt said.
But those reforms amount to a distraction from the real changes needed at FDA, said Dr. Sidney Wolfe, of the consumer group Public Citizen. Wolfe wants to see the FDA grant more independence to its Office of Drug Safety, which currently reviews safety information about drugs on the market.
Public Citizen called three weeks ago for FDA to require that Pfizer, the maker of Celebrex, place a "black box" warning label on the medicine. A black box is the strongest warning that can be applied to a medicine; the FDA responded last year to public concerns about the safety of antidepressant use in teens by requiring that black box warnings be placed on a number of medicines.
The FDA's arthritis and drug safety and risk management advisory committees will meet for three days this week to consider all the safety information available about the pain medicines.
Committee members will be asked to consider several questions about whether companies should be allowed to continue marketing the drugs. And, if marketing can continue, how much and what kind of information should drug companies be required to provide to patients?
FDA also wants the committees to consider whether there is a patient population for whom the risk of cox-2 inhibitors is warranted, given the potential for benefit.
The last question is key to Dr. Jack Kabazie, medical director of the Institute for Pain Medicine at West Penn Hospital.
"I continue to prescribe Bextra and Celebrex," he said. "I believe there's a class of patients who can be on the medicines, and there are those who should not be on the medicines."
More than $5.3 billion worth of Vioxx, Celebrex and Bextra were purchased in the United States during 2004, according to IMS Health, although sales clearly tapered off at the end of the year.
In a report released this week, IMS Health said 2004 was the first year since 1995 that the pharmaceutical industry had scored less than double-digit growth. Safety concerns about cox-2 inhibitors were among the contributing factors.
The bad news about arthritis medicines even included troubling information in December about naproxen, a drug marketed by Bayer over-the-counter as Aleve. Bayer has its North American headquarters in Robinson.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.